MANNKIND CORP Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options (Deprecated 2017-01-31)
MANNKIND CORP (MNKD) reported Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options (Deprecated 2017-01-31) of $500.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-16.
Discontinued › Notes › Compensation Related Costs
us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions · last filed 2017-03-16
- MANNKIND CORP employee service share-based compensation, cash received from exercise of stock options (deprecated 2017-01-31) for fiscal 2016 was $500.00K, a 84.85% decline from fiscal 2015.
- MANNKIND CORP employee service share-based compensation, cash received from exercise of stock options (deprecated 2017-01-31) for fiscal 2015 was $3.30M, a 70.00% decline from fiscal 2014.
- MANNKIND CORP employee service share-based compensation, cash received from exercise of stock options (deprecated 2017-01-31) for fiscal 2014 was $11.00M, a 378.26% increase from fiscal 2013.
- MANNKIND CORP employee service share-based compensation, cash received from exercise of stock options (deprecated 2017-01-31) for fiscal 2013 was $2.30M, a 24900.00% increase from fiscal 2012.
| Period end | Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options (Deprecated 2017-01-31) 12 month |
|---|---|
| 2016-12-31 | $500.00K 10-K · filed 2017-03-16 |
| 2015-12-31 | $3.30M 10-K · filed 2017-03-16 |
| 2014-12-31 | $11.00M 10-K · filed 2017-03-16 |
| 2013-12-31 | $2.30M 10-K · filed 2016-03-15 |
| 2012-12-31 | $9.20K 10-K · filed 2015-03-02 |
| 2011-12-31 | $625.00K 10-K · filed 2014-03-03 |
| 2010-12-31 | $924.00K 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |